Global pharma giant Pfizer is set to make a major impact at the American Society of Clinical Oncology Annual Meeting 2026, unveiling a sweeping wave of cancer research that could reshape treatment standards across multiple tumor types.
At the high-profile gathering in Chicago from May 29 to June 2, the drugmaker will present data from more than 40 studies—including three late-breaking sessions—signalling an aggressive push to move breakthrough therapies earlier in the course of disease and expand options for patients.
“For people living with cancer and their families, every moment matters. We are moving with urgency to drive advances that have the potential to change standards of care – and striving to bring new, innovative options to patients in earlier lines of therapy,” said Jeff Legos, Chief Oncology Officer, Pfizer.
“Our progress is evident in the data presented at ASCO this year, which span our portfolio of established therapies, as well as next-generation, early-stage clinical research from one of the industry’s largest oncology R&D programs. Together, these results reinforce our ability to advance breakthroughs that may redefine clinical practice and change the lives of people with cancer.”
Among the headline-grabbing results: a seven-year update from the pivotal CROWN study strengthens the case for LORBRENA (lorlatinib) as a frontline standard for ALK-positive metastatic non-small cell lung cancer—one of the longest follow-ups in this setting.
Meanwhile, a late-breaking analysis from the BREAKWATER trial could further cement a combination regimen anchored by BRAFTOVI (encorafenib) as a first-line option for patients with BRAF V600E-mutant metastatic colorectal cancer, building on its recent regulatory momentum.
Pfizer is also zeroing in on earlier intervention. New Phase 3 data from the TALAPRO-3 study show strong progression-free survival gains for TALZENNA (talazoparib) plus XTANDI (enzalutamide) in metastatic castration-sensitive prostate cancer—hinting at a shift toward earlier use in genetically defined patients.
In breast cancer, results from the HER2CLIMB-05 trial suggest TUKYSA (tucatinib) could help enable chemotherapy-free maintenance strategies for HER2-positive metastatic disease—an approach that could significantly ease treatment burden.
Beyond established drugs, Pfizer is spotlighting a deep pipeline of experimental therapies designed to attack cancer in new ways. These include a novel PD-1/VEGF bispecific antibody, next-generation antibody-drug conjugates, and targeted combinations aimed at difficult-to-treat tumors like melanoma and lung cancer.
Early-stage data on atirmociclib, a selective CDK4 inhibitor, and new brain-penetrant targeted therapies underscore the company’s ambition to build “backbone” treatments that can be used across multiple cancers and lines of therapy.
